Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
FATE
SELLFate Therapeutics, Inc. · Healthcare · United States · $281M · Avg Vol: $10M/d
COMPANY DESCRIPTION
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company pioneering the development of programmed cellular immunotherapies, specifically induced pluripotent stem cell (iPSC)-derived natural killer (NK) and T-cell product candidates for cancer and autoimmune diseases. Its innovative iPSC platform represents a differentiated approach to cell therapy manufacturing, offering potential for off-the-shelf treatments. The company is a key player in the nascent but rapidly evolving allogeneic cell therapy space.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 96.3M | 63.5M | 13.6M | 6.6M | -59.0% | 6.3M | 5.2M | 5.2M | -11.2% |
| EPS | -2.91 | -1.64 | -1.64 | -1.15 | — | -1.10 | -1.04 | -0.99 | — |
| Shares | 97.3M | 98.6M | 113.9M | 115.4M | +18.6% | 116.6M | — | — | — |
| Debt | 109.3M | 103.5M | 85.3M | 77.8M | -10.7% | 76.8M | — | — | — |
| Equity | 483.9M | 368.4M | 318.7M | 207.2M | -24.6% | — | — | — | — |
| Op CF | -248.2M | -132.3M | -122.9M | -106.1M | — | -103.1M | — | — | — |
| Inv CF | 166.8M | 112.7M | 12.2M | 111.2M | — | — | — | — | — |
| Fin CF | 9.2M | 85.0K | 99.9M | 5.5M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of FATE are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| FATE | Fate Therapeutics, Inc.(you) | $281M | 26 | SELL |
| SABS | SAB Biotherapeutics, Inc. | $268M | 27 | SELL |
| VNDA | Vanda Pharmaceuticals Inc. | $312M | 26 | SELL |
| MGNX | MacroGenics, Inc. | $235M | 26 | SELL |
| ZNTL | Zentalis Pharmaceuticals, Inc. | $308M | 28 | SELL |
| PRLD | Prelude Therapeutics Incorporated | $305M | 24 | SELL |
| IMRX | Immuneering Corporation | $279M | 21 | SELL |
| ALXO | ALX Oncology Holdings Inc. | $273M | 31 | SELL |
| OABI | OmniAb, Inc. | $294M | 32 | SELL |
| PALI | Palisade Bio, Inc. | $339M | 29 | SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.6%